New hope for Tough-to-Treat lung cancer: trial tests targeted combo
NCT ID NCT07472478
Summary
This study is testing a new combination of drugs given before and after surgery for patients with a specific genetic type of lung cancer (called KRAS G12C). The goal is to see if this approach can shrink or eliminate the cancer in the tumor before it's removed and prevent it from coming back. It will enroll about 32 adults with early-to-mid stage lung cancer who have not had any prior cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.